RT Journal Article
SR Electronic
T1 Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.17.20134031
DO 10.1101/2020.06.17.20134031
A1 Salton, Francesco
A1 Confalonieri, Paola
A1 Santus, Pierachille
A1 Harari, Sergio
A1 Scala, Raffaele
A1 Lanini, Simone
A1 Vertui, Valentina
A1 Oggionni, Tiberio
A1 Caminati, Antonella
A1 Patruno, Vincenzo
A1 Tamburrini, Mario
A1 Scartabellati, Alessandro
A1 Parati, Mara
A1 Villani, Massimiliano
A1 Radovanovic, Dejan
A1 Tomassetti, Sara
A1 Ravaglia, Claudia
A1 Poletti, Venerino
A1 Vianello, Andrea
A1 Gaccione, Anna Talia
A1 Guidelli, Luca
A1 Raccanelli, Rita
A1 Lucernoni, Paolo
A1 Lacedonia, Donato
A1 Foschino Barbaro, Maria Pia
A1 Centanni, Stefano
A1 Mondoni, Michele
A1 Davì, Matteo
A1 Fantin, Alberto
A1 Cao, Xueyuan
A1 Torelli, Lucio
A1 Zucchetto, Antonella
A1 Montico, Marcella
A1 Casarin, Annalisa
A1 Romagnoli, Micaela
A1 Gasparini, Stefano
A1 Bonifazi, Martina
A1 D’Agaro, Pierlanfranco
A1 Marcello, Alessandro
A1 Licastro, Danilo
A1 Ruaro, Barbara
A1 Volpe, Maria Concetta
A1 Umberger, Reba
A1 Meduri, Umberto
A1 Confalonieri, Marco
YR 2020
UL http://medrxiv.org/content/early/2020/06/25/2020.06.17.20134031.abstract
AB Background In hospitalized patients with COVID-19 pneumonia, progression to acute respiratory failure requiring invasive mechanical ventilation (MV) is associated with significant morbidity and mortality. Severe dysregulated systemic inflammation is the putative mechanism. We hypothesize that early prolonged methylprednisolone (MP) treatment could accelerate disease resolution, decreasing the need for ICU and mortality.Methods We conducted a multicenter, observational study to explore the association between exposure to prolonged, low-dose, MP treatment and need for ICU referral, intubation or death within 28 days (composite primary endpoint) in patients with severe COVID-19 pneumonia admitted to Italian respiratory high-dependency units. Secondary outcomes were invasive MV-free days and changes in C-reactive protein (CRP) levels.Results Findings are reported as MP (n=83) vs. control (n=90). The composite primary endpoint was met by 19 vs. 40 [adjusted hazard ratio (HR) 0.41; 95% confidence interval (CI): 0.24-0.72]. Transfer to ICU and need for invasive MV was necessary in 15 vs. 27 (p=0.07) and 14 vs. 26 (p=0.10), respectively. By day 28, the MP group had fewer deaths (6 vs. 21, adjusted HR=0.29; 95% CI: 0.12-0.73) and more days off invasive MV (24.0 ± 9.0 vs. 17.5 ± 12.8; p=0.001). Study treatment was associated with rapid improvement in PaO2:FiO2 and CRP levels. The complication rate was similar for the two groups (p=0.84).Conclusion In patients with severe COVID-19 pneumonia, early administration of prolonged MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence. Randomized controlled studies are needed to confirm these findings.Registration ClinicalTrials.gov. Identifier: NCT04323592Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04323592Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04323592?term=confalonieri&draw=2&rank=1 Funding StatementThis material is the result of work supported with the resources and use of facilities at the University Hospital of Trieste and Memphis VA Medical Center. The contents of this commentary do not represent the views of the US Department of Veterans Affairs nor of the United States or Italian Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the referral Ethics Committee for the Coordinating Centre (University Hospital of Trieste, #CEUR-2020-Os-052).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available on reasonable external request.